C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
Background. Our aim was to define the conditions that affect therapeutic success when dipeptidyl peptidase-4 (DPP-4) inhibitor is added to metformin monotherapy. Materials and Methods. We reviewed the medical records of 56 patients who had received DPP-4 inhibitor as an add-on to metformin monothera...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2016/4509603 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545413842862080 |
|---|---|
| author | Sevin Demir Sule Temizkan Mehmet Sargin |
| author_facet | Sevin Demir Sule Temizkan Mehmet Sargin |
| author_sort | Sevin Demir |
| collection | DOAJ |
| description | Background. Our aim was to define the conditions that affect therapeutic success when dipeptidyl peptidase-4 (DPP-4) inhibitor is added to metformin monotherapy. Materials and Methods. We reviewed the medical records of 56 patients who had received DPP-4 inhibitor as an add-on to metformin monotherapy and evaluated their response in the first year of therapy. Fasting blood glucose (FBG), HbA1c, C-peptide, and weight of the patients were recorded at 3-month intervals during the first year of treatment. Results. Patients who added DPP-4 inhibitor to metformin monotherapy had significant weight loss (P=0.004) and FBG and HbA1c levels were significantly lowered during the first 6 months (both P<0.001). Baseline levels of C-peptide were predictive for success of the treatment (P=0.02), even after correction for confounding factors, for example, age, gender, or BMI (P=0.03). Duration of diabetes was not a predictor of response to treatment (P=0.60). Conclusion. Our study demonstrates that in patients having inadequate glycemic control, the addition of a DPP-4 inhibitor as a second oral agent to metformin monotherapy provides better glycemic control, protects β-cell reserves, and does not cause weight gain. These effects depend on baseline C-peptide levels. |
| format | Article |
| id | doaj-art-fa2661cbdaa742eba8a0ff1c6fe39727 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-fa2661cbdaa742eba8a0ff1c6fe397272025-02-03T07:25:55ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/45096034509603C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor TherapySevin Demir0Sule Temizkan1Mehmet Sargin2Department of Family Medicine, Eleskirt Public Hospital, 04600 Agri, TurkeyDepartment of Endocrinology and Metabolic Diseases, Kartal Dr. Lutfi Kirdar Training and Research Hospital, 34890 Istanbul, TurkeyDepartment of Family Medicine, Medeniyet University Goztepe Training and Research Hospital, 34722 Istanbul, TurkeyBackground. Our aim was to define the conditions that affect therapeutic success when dipeptidyl peptidase-4 (DPP-4) inhibitor is added to metformin monotherapy. Materials and Methods. We reviewed the medical records of 56 patients who had received DPP-4 inhibitor as an add-on to metformin monotherapy and evaluated their response in the first year of therapy. Fasting blood glucose (FBG), HbA1c, C-peptide, and weight of the patients were recorded at 3-month intervals during the first year of treatment. Results. Patients who added DPP-4 inhibitor to metformin monotherapy had significant weight loss (P=0.004) and FBG and HbA1c levels were significantly lowered during the first 6 months (both P<0.001). Baseline levels of C-peptide were predictive for success of the treatment (P=0.02), even after correction for confounding factors, for example, age, gender, or BMI (P=0.03). Duration of diabetes was not a predictor of response to treatment (P=0.60). Conclusion. Our study demonstrates that in patients having inadequate glycemic control, the addition of a DPP-4 inhibitor as a second oral agent to metformin monotherapy provides better glycemic control, protects β-cell reserves, and does not cause weight gain. These effects depend on baseline C-peptide levels.http://dx.doi.org/10.1155/2016/4509603 |
| spellingShingle | Sevin Demir Sule Temizkan Mehmet Sargin C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy Journal of Diabetes Research |
| title | C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy |
| title_full | C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy |
| title_fullStr | C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy |
| title_full_unstemmed | C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy |
| title_short | C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy |
| title_sort | c peptide levels predict the effectiveness of dipeptidyl peptidase 4 inhibitor therapy |
| url | http://dx.doi.org/10.1155/2016/4509603 |
| work_keys_str_mv | AT sevindemir cpeptidelevelspredicttheeffectivenessofdipeptidylpeptidase4inhibitortherapy AT suletemizkan cpeptidelevelspredicttheeffectivenessofdipeptidylpeptidase4inhibitortherapy AT mehmetsargin cpeptidelevelspredicttheeffectivenessofdipeptidylpeptidase4inhibitortherapy |